ADCC is a critical mechanism leveraged in immunotherapy, particularly in treatments involving monoclonal antibodies designed to target cancer cells. Drugs like rituximab and trastuzumab work by binding to antigens on cancer cells, leading to their destruction via ADCC. Enhancing ADCC can significantly improve the efficacy of these therapies.